Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow (NASDAQ:ALMS) 2026-09-04
· seekingalpha.com
2026-09-04. The following slide deck was published by Alumis Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...